Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors

Abstract

Anti-vascular endothelial growth factor (VEGF) treatment maintains vision in most and improves vision in a considerable proportion of patients with neovascular age-related macular degeneration (nvAMD). Treatment outcomes in routine medical care seem to be best with a Treat & Extend regimen. However, overall results in routine medical care are lacking behind those achieved in highly standardized clinical phase III trials of monthly anti-VEGF treatment for a number of reasons, such as different patient populations and less intense treatment. Several clinical factors can predict anti-VEGF treatment outcomes. Those who present at a younger age, with better baseline vision and smaller CNV lesions..